Merkel Cell Carcinoma Clinical Trials & Research

Although the rarity of Merkel cell carcinoma has made it difficult to study, researchers at Memorial Sloan Kettering Cancer Center have a specific interest in evaluating new ways to treat this disease.

We have a number of clinical trials evaluating new treatments for Merkel cell carcinoma. Some of these trials are focused on combining different treatments — for example, using more than one type of immunotherapy, or combing immunotherapy with different types of radiation. We are also looking at targeted therapies for some cases of Merkel cell carcinoma.

and/or
2 Clinical Trials found
A Phase 1 Study of CRD3874-SI in People With Advanced Sarcoma or Merkel Cell Cancer
Researchers want to find the best dose of CRD3874-SI to use in people with sarcoma or Merkel cell carcinoma (MCC). The people in this study have sarcoma or MCC that has spread. CRD3874-SI attaches to a type of protein called a STING. This protein encourages immune cells to kill cancer cells, which may slow or stop cancer growth. CRD3874-SI is given intravenously (by vein).
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau
A Phase 1 Study of MQ710 in People With Solid Tumors
In this study, researchers are finding the highest dose of MQ710 to use safely in people with certain types of advanced cancer. The people in this study have solid tumors that came back or grew even after treatment. In a later part of the study, the researchers will assess MQ710 plus another drug called pembrolizumab.
New York City, Commack, Basking Ridge, Westchester, Monmouth, Bergen, Nassau